BioNTech
BiotechMainz, Germany, Germany · Est. 2008 · 5,200 employees
BioNTech is a German biotechnology company that develops mRNA-based therapeutics and vaccines for cancer and infectious diseases.
26
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
20
Indications↗
Distinct diseases across all programs
106
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
26 drugs in development
Phase 212
Phase 17
Preclinical12
By Therapeutic Area
top 2
Oncology
2175%
Infectious Disease
518%
R&D Momentum
65/100
Pipeline Velocity
39/100
Trial Completion Rate
81/100
Pipeline Concentration
60/100
Pipeline Freshness
83/100
Strategic Signals
- ↗Early-stage heavy pipeline may seek late-stage partners
Activity
Recent Activity
Last 14 days
Nov 3, 2026
Recruiting
A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer
Oct 31, 2026
Recruiting
A Phase III, Multisite, Randomized, Double-Blind Trial of BNT327 in Combination With Chemotherapy Versus Placebo With Chemotherapy in Patients With Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC Determined Ineligible for PD(L)1 Therapy Based on PD-L1 Negative Disease
Oct 29, 2026
Active, not recruiting
An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1
Oct 29, 2026
Recruiting
A Phase II, Multi-site, Open-label Trial Evaluating the Safety and Efficacy of Pumitamig and Bevacizumab as Monotherapy and Pumitamig in Combination With Temozolomide in Patients With Recurrent Glioblastoma
Oct 23, 2026
Recruiting
A Phase Ib/II, Multi-site, Open-label, Dose Finding Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT326 in Combination With BNT327 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
Oct 23, 2026
Active, not recruiting
Phase I, Randomized, Observer-blinded, 3-part, Dose Escalation and Expanded Safety and Dose Evaluation Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Prophylactic Vaccine for the Prevention of Genital Lesions Caused by Herpes Simplex Virus (HSV)-2 and Potentially HSV-1
Earlier
Oct 17, 2026TrialA Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer
Oct 17, 2026TrialA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL STUDY EVALUATING THE SAFETY, TOLERABILITY, IMMUNOGENICITY AND EFFICACY OF A VARIANT-ADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE
2 more events
Oct 17, 2026TrialA Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer
Oct 16, 2026TrialA Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With BNT327 in Participants With Advanced Breast Cancer
Details
Company Info
Company Overview
$26.0B
Mkt Cap
$18.0B
Revenue
—
Cash
CEOUgur Sahin
Founded2008
Employees5,200
HQMainz, Germany, Germany
Websitebiontech.de
LinkedInCompany Page
Therapeutic Focus
oncologyinfectious diseasesimmunotherapypersonalized medicine
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Infectious Disease(5 drugs)
—
2
3
—
—
Infectious Disease(5 drugs)
Oncology(21 drugs)
11
5
9
—
—
Oncology(21 drugs)
Unknown / Other(2 drugs)
2
—
—
—
—
Unknown / Other(2 drugs)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)